

**Biosimilars: Global Markets**

Market Research Report | 2025-03-18 | 219 pages | BCC Research

**AVAILABLE LICENSES:**

- Single User License \$4650.00
- 2-5 Users License \$5580.00
- Site License \$6696.00
- Enterprise License \$8035.00

**Report description:**

## Description

## Report Scope

This report provides the current and future market potential of biosimilars, with market projections through 2029; and it includes a detailed analysis of the drivers, restraints and opportunities in the biosimilars market. The report also covers the competitive environment of the biosimilars industry and features a product analysis.

For this analysis, the market for biosimilars is segmented based on product type, therapeutic application and region. Based on product type, it is segmented into monoclonal antibodies, recombinant growth factors, recombinant hormones, fusion protein and others (such as LMWHs and interferons). Based on therapeutic application, the market is segmented into the following: cancer and related disorders, autoimmune and inflammatory diseases, diabetes, anemia, growth hormone deficiency and other diseases.

Based on geographical region, the biosimilars market is segmented into the following: North America, Europe, Asia-Pacific and the Rest of the World (RoW). The North American region includes the U.S., Canada and Mexico. Europe includes Germany, the U.K., Italy, France, Spain and the Rest of Europe; Asia-Pacific includes China, Japan, India, Australia, South Korea and the Rest of Asia-Pacific. For market estimate data, 2021 and 2022 serve as the historical years, 2023 as the base year, and 2029 as the forecast year.

The report provides company profiles of key players in the biosimilars market that feature detailed information about each organization's business segments, financials, product portfolios and recent developments.

## Report Includes

- 142 data tables and 74 additional tables
- An analysis of the global market trends for biosimilars, with historic revenue data (sales figures) from 2021 and 2022, estimates for 2023, forecast for 2024, and projected CAGRs through 2029
- Estimates of the market size and revenue growth prospects, along with a market share analysis by product type and sub-type, therapeutic application, and region
- Facts and figures pertaining to the market dynamics, advances in existing biosimilars, regulations and the impact of

macroeconomic factors

- Review of the industry structure, emerging trends and developments, clinical trials and approvals, and new product
- Insights derived from the Porter's Five Forces model, as well as global supply chain and PESTLE analyses
- An analysis of key patent publications, grants and applications in biosimilars
- Analysis of the competitive landscape featuring companies' market shares, strategic alliances, M&A activity and a venture funding outlook
- Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and ESG scores and practices of leading companies
- Profiles of the market leaders, including Amgen Inc., Sandoz Group AG, Biocon Biologics Ltd., Pfizer Inc., and Teva Pharmaceutical Industries Ltd.

## Executive Summary

### Summary:

The global biosimilars market was valued at \$23.8 billion in 2023. The market is expected to grow from \$28.5 billion in 2024 to \$69.2 billion by 2029, at a compound annual growth rate (CAGR) of 19.4% from 2024 through 2029.

In 2023, the global market for biosimilars was valued at \$23.8 billion. This market is forecast to grow at a compound annual growth rate (CAGR) of 19.4% to reach \$69.2 billion at the end of 2029.

The two major factors driving the growth of this market are patent expirations of major biologics and the cost-effectiveness and healthcare savings associated with using biosimilars. In the meantime, the factors restraining growth are intellectual property issues, legal issues and manufacturing and supply chain complexities.

The largest share in terms of product type of the global biosimilars market in 2023 was held by monoclonal antibodies; this is expected to grow at a CAGR of 19.8% during the forecast period.

In terms of therapeutic application, the autoimmune and inflammatory diseases segment is forecasted to grow at the fastest CAGR of 20.1% throughout the forecast period. However, the cancer and related disorders segment held for the largest share of 34.2% of the global biosimilars market in 2023, and it is expected to reach a value of \$24 billion by 2029.

In terms of region, Europe held the largest market share of 45.8% in 2023. Early adoption and supportive regulatory frameworks, as well as high market penetration coupled with government policies and incentives, are responsible for the European region's large share.

### Table of Contents:

Table of Contents

Chapter 1 Executive Summary

Market Outlook

Scope of Report

Market Insights

Chapter 2 Market Overview

Introduction

Terminology of Biosimilars

Key Terms in Biosimilars

WHO Guidelines on Evaluation of Biosimilars

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

[www.scotts-international.com](http://www.scotts-international.com)

Pharmacovigilance/Post-Approval Monitoring

Biosimilars Vs. Biobetters

Popular Types of Biosimilars

Recombinant Hormones

Recombinant Growth Factors

Monoclonal Antibodies (mAbs)

Fusion Proteins

Interferons

Low Molecular Weight Heparins (LMWHs)

Chapter 3 Market Dynamics

Introduction

Market Drivers

Patent Expirations of Major Biologics

Cost-effectiveness and Healthcare Savings

Market Restraints

Intellectual Property and Legal Issues

Manufacturing and Supply Chain Complexities

Market Opportunities

Increasing Access, Adoption and Awareness

Emerging Markets

Chapter 4 Emerging Technologies

Advanced Analytical Techniques

Single-use Bioreactors

Cell Line Engineering and Expression Systems

Chapter 5 Market Segmentation Analysis

Segmentation Breakdown

Global Biosimilars Market, by Product Type

Monoclonal Antibodies

Recombinant Growth Factors

Recombinant Hormones

Fusion Protein

Others

Global Biosimilars Market, by Therapeutic Application

Cancer and Related Disorders

Autoimmune and Inflammatory Diseases

Diabetes

Anemia

Growth Hormone Deficiency

Other Diseases

Geographic Breakdown

Global Biosimilars Market, by Region

Market Size and Forecast

North America

Europe

Asia-Pacific

Rest of the World (RoW)

Chapter 6 Competitive Landscape and Patent Analysis

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Overview

Key Market Leaders

Emerging Players

Strategic Analysis

Challenges and Future Trends

Patent Analysis

Patent Regulations in Favor of Branded Biologics

Market Exclusivity

Chapter 7 Regulatory Aspects

Overview

Biosimilar Regulations in Europe

Biosimilar Regulations in the U.S.

Principle of Exclusivity

Biosimilar Regulations in China

Chapter 8 Sustainability in the Global Biosimilars Market: An ESG Perspective

Introduction to ESG

ESG Performance in the Market

ESG Practices in the Biosimilars Industry

Environmental Performance

Concluding Remarks from BCC Research

Chapter 9 Appendix

Research Methodology

Sources

Abbreviations

Company Profiles

ACCORD BIOPHARMA INC.

ALVOTECH

AMGEN INC.

AMNEAL PHARMACEUTICALS LLC.

BIOCON BIOLOGICS LTD.

BIOGEN

CELLTRION INC.

COHERUS BIOSCIENCES

FRESENIUS KABI AG

LILLY

PFIZER INC.

SAMSUNG BIOEPIS

SANDOZ GROUP AG

TEVA PHARMACEUTICAL INDUSTRIES LTD.

VIATRIS INC.

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

[www.scotts-international.com](http://www.scotts-international.com)

## Biosimilars: Global Markets

Market Research Report | 2025-03-18 | 219 pages | BCC Research

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

### ORDER FORM:

Select license	License	Price
	Single User License	\$4650.00
	2-5 Users License	\$5580.00
	Site License	\$6696.00
	Enterprise License	\$8035.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	Phone*
<input type="text"/>	<input type="text"/>
First Name*	Last Name*
<input type="text"/>	<input type="text"/>
Job title*	
<input type="text"/>	
Company Name*	EU Vat / Tax ID / NIP number*
<input type="text"/>	<input type="text"/>
Address*	City*
<input type="text"/>	<input type="text"/>
Zip Code*	Country*
<input type="text"/>	<input type="text"/>
	Date
	<input type="text" value="2026-02-12"/>

Signature

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

[www.scotts-international.com](http://www.scotts-international.com)



**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

[www.scotts-international.com](http://www.scotts-international.com)